Cover Image
市場調查報告書

ZIOPHARM Oncology, Inc. - 產品平台分析

ZIOPHARM Oncology, Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 204935
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
ZIOPHARM Oncology, Inc. - 產品平台分析 ZIOPHARM Oncology, Inc. - Product Pipeline Review - 2014
出版日期: 2014年07月22日 內容資訊: 英文 46 Pages
簡介

ZIOPHARM Oncology, Inc. ha是致力於研究開發治療癌症用藥物的生物製藥公司。

本報告提供ZIOPHARM Oncology, Inc.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

ZIOPHARM Oncology, Inc.的基本資料

ZIOPHARM Oncology, Inc.概要

  • 主要資訊
  • 企業資料

ZIOPHARM Oncology, Inc.:R&D概要

  • 主要的治療範圍

ZIOPHARM Oncology, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

ZIOPHARM Oncology, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式

ZIOPHARM Oncology, Inc.

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

ZIOPHARM Oncology, Inc.:藥物簡介

  • palifosfamide
  • Ad-RTS-IL-12
  • darinaparsin
  • indibulin
  • DC-RTS-IL-12
  • Cell Therapy for Cancer
  • Drug for Cancer
  • Immunotherapy Program
  • Multigenic Program For Cancer
  • RheoSwitch Regulated interferon alpha

ZIOPHARM Oncology, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

ZIOPHARM Oncology, Inc.:最近的開發平台趨勢

ZIOPHARM Oncology, Inc.:暫停中的計劃

ZIOPHARM Oncology, Inc.:中止開發的開發中產品

  • 中止開發的開發中產品簡介

ZIOPHARM Oncology, Inc.:總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC05300CDB

Summary

Global Markets Direct's, 'ZIOPHARM Oncology, Inc. - Product Pipeline Review - 2014', provides an overview of the ZIOPHARM Oncology, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ZIOPHARM Oncology, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ZIOPHARM Oncology, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ZIOPHARM Oncology, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ZIOPHARM Oncology, Inc.'s pipeline products

Reasons to buy

  • Evaluate ZIOPHARM Oncology, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ZIOPHARM Oncology, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ZIOPHARM Oncology, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ZIOPHARM Oncology, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ZIOPHARM Oncology, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ZIOPHARM Oncology, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ZIOPHARM Oncology, Inc. Snapshot
    • ZIOPHARM Oncology, Inc. Overview
    • Key Information
    • Key Facts
  • ZIOPHARM Oncology, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • ZIOPHARM Oncology, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • ZIOPHARM Oncology, Inc. - Pipeline Products Glance
    • ZIOPHARM Oncology, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • ZIOPHARM Oncology, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • ZIOPHARM Oncology, Inc. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
  • ZIOPHARM Oncology, Inc. - Drug Profiles
    • palifosfamide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ad-RTS-IL-12
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • darinaparsin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • indibulin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DC-RTS-IL-12
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Immunotherapy Program
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Multigenic Program For Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RheoSwitch Regulated interferon alpha
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ZIOPHARM Oncology, Inc. - Pipeline Analysis
    • ZIOPHARM Oncology, Inc. - Pipeline Products by Target
    • ZIOPHARM Oncology, Inc. - Pipeline Products by Route of Administration
    • ZIOPHARM Oncology, Inc. - Pipeline Products by Molecule Type
    • ZIOPHARM Oncology, Inc. - Pipeline Products by Mechanism of Action
  • ZIOPHARM Oncology, Inc. - Recent Pipeline Updates
  • ZIOPHARM Oncology, Inc. - Dormant Projects
  • ZIOPHARM Oncology, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • palifosfamide
  • ZIOPHARM Oncology, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ZIOPHARM Oncology, Inc., Key Information
  • ZIOPHARM Oncology, Inc., Key Facts
  • ZIOPHARM Oncology, Inc. - Pipeline by Indication, 2014
  • ZIOPHARM Oncology, Inc. - Pipeline by Stage of Development, 2014
  • ZIOPHARM Oncology, Inc. - Monotherapy Products in Pipeline, 2014
  • ZIOPHARM Oncology, Inc. - Phase III, 2014
  • ZIOPHARM Oncology, Inc. - Phase II, 2014
  • ZIOPHARM Oncology, Inc. - Phase I, 2014
  • ZIOPHARM Oncology, Inc. - IND/CTA Filed, 2014
  • ZIOPHARM Oncology, Inc. - Preclinical, 2014
  • ZIOPHARM Oncology, Inc. - Pipeline by Target, 2014
  • ZIOPHARM Oncology, Inc. - Pipeline by Route of Administration, 2014
  • ZIOPHARM Oncology, Inc. - Pipeline by Molecule Type, 2014
  • ZIOPHARM Oncology, Inc. - Pipeline Products by Mechanism of Action, 2014
  • ZIOPHARM Oncology, Inc. - Recent Pipeline Updates, 2014
  • ZIOPHARM Oncology, Inc. - Dormant Developmental Projects,2014
  • ZIOPHARM Oncology, Inc. - Discontinued Pipeline Products, 2014

List of Figures

  • ZIOPHARM Oncology, Inc. - Pipeline by Top 10 Indication, 2014
  • ZIOPHARM Oncology, Inc. - Pipeline by Stage of Development, 2014
  • ZIOPHARM Oncology, Inc. - Monotherapy Products in Pipeline, 2014
  • ZIOPHARM Oncology, Inc. - Pipeline by Top 10 Target, 2014
  • ZIOPHARM Oncology, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • ZIOPHARM Oncology, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • ZIOPHARM Oncology, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top